• Home
  • Entertainment News
  • Viral
  • BBNaija
  • Nigerian Music
  • Relationship
  • Quiz
  • Memes
  • Contact Us
  • Advertise
Wednesday, September 30, 2026
YabaLeftOnline
  • Home
  • Entertainment News
  • Viral News
  • News
No Result
View All Result
  • Home
  • Entertainment News
  • Viral News
  • News
No Result
View All Result
YabaLeftOnline
No Result
View All Result
Home News

New COVID-19 medicine, Dexamethasone has not been approved in Nigeria – NCDC

Dotun Abiola by Dotun Abiola
June 17, 2020
Reading Time: 1 min read
“Coronavirus will surely get to every state” – NCDC
Share on FacebookShare on Twitter

he Nigeria Centre for Disease Control (NCDC) has said that the new COVID-19 drug, Dexamethasone is yet to be approved for use in treatment of patients with the viral disease in Nigeria.

ReadAlso

What is the capacity of these isolation centers NCDC? – Nigerians asks as Lagos records 378 new cases of COVID-19 in a day

#COVID-19: Recovered patients in Nigeria surpass 1,000

The low-dose steroid treatment dexamethasone is a major breakthrough in the fight against the deadly virus, UK experts say. It considerably reduce the risk of patients dying from COVID-19.

In a series of tweet, the NCDC said it is aware of the drug, however the drug has not yet been approved for use in Nigeria.

“The Nigeria Centre for Disease Control (NCDC) is aware of recent outcomes from a UK-Government funded clinical trial for COVID-19. The results support the use of Dexamethasone as a possible treatment to reduce the risk of death among COVID-19 patients, who require oxygen or mechanical ventilation.

Please note that the Government of Nigeria has not validated or approved any treatment for COVID-19. In addition, the use of Dexamethasone for COVID-19 treatment has not been validated by WHO.

We are aware of ongoing clinical trials conducted by scientists in the UK and will work with our sister agencies to evaluate this emerging data on the use of Dexamethasone. We will inform the general public on outcomes following scientific review and validation.” the NCDC tweet reads.

Tags: NCDC

Related Posts

What is the capacity of these isolation centers NCDC? – Nigerians asks as Lagos records 378 new cases of COVID-19 in a day

What is the capacity of these isolation centers NCDC? – Nigerians asks as Lagos records 378 new cases of COVID-19 in a day

May 31, 2020
“Coronavirus will surely get to every state” – NCDC

#COVID-19: Recovered patients in Nigeria surpass 1,000

May 14, 2020
NCDC reveals number of Coronavirus test conducted in Nigeria

NCDC reveals number of Coronavirus test conducted in Nigeria

April 13, 2020
#Covid-19: NCDC officials take sample from a UK-returnee in her home (Video)

#Covid-19: NCDC officials take sample from a UK-returnee in her home (Video)

March 29, 2020
#Covid-19: NCDC issues warning after they reached out to an Instagram user who claimed he needed urgent help only to discover it was a skit

#Covid-19: NCDC issues warning after they reached out to an Instagram user who claimed he needed urgent help only to discover it was a skit

March 26, 2020
‘Nigeria needs N4bn to tackle infectious diseases’ – NCDC

‘Nigeria needs N4bn to tackle infectious diseases’ – NCDC

August 6, 2018
Next Post
BBNaija’s Jackye Madu reportedly dumped her boyfriend Lami for a young tech entrepreneur he introduced her to [Details]

BBNaija's Jackye Madu reportedly dumped her boyfriend Lami for a young tech entrepreneur he introduced her to [Details]

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • Advertise
  • Write For Us
  • Contact Us
Call us: +234 903 171 3513

© 2022 YABALEFTONLINE MEDIA

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Home
  • Entertainment News
  • Viral
  • BBNaija
  • Nigerian Music
  • Relationship
  • Quiz
  • Memes
  • Contact Us
  • Advertise

© 2022 YABALEFTONLINE MEDIA

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.